Expert Ratings for Gain Therapeutics
Analysts have provided the following ratings for Gain Therapeutics (NASDAQ:GANX) within the last quarter: Bullish Somewhat Bullish Indifferent…
Analyst Ratings for Gain Therapeutics
Over the past 3 months, 4 analysts have published their opinion on Gain Therapeutics (NASDAQ:GANX) stock. These analysts…
HC Wainwright & Co. Maintains Buy on Gain Therapeutics, Lowers Price Target to $10
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Gain Therapeutics (NASDAQ:GANX) with a Buy and lowers the price target from $12 to $10.
Gain Therapeutics Highlights Presentation Of Preclinical Data Demonstrating Potential Disease Modifying Benefits Of Its Novel Brain Penetrant Small Molecule Candidate GT-02287 In Two Preclinical Models Of Parkinson’s Disease
Treatment with GT-02287 Resulted in a Significant Dose-Dependent Improvement of Cellular Lysosomal Health and Fine Motor Skills
Results Presented at the International Congress of Parkinson's Disease and
Looking Into Gain Therapeutics’s Return On Capital Employed
Gain Therapeutics (NASDAQ:GANX) brought in sales totaling $95 thousand during Q2 according to data provided by Benzinga Pro. However, earnings decreased 55.39%, resulting in a loss of $5.09 million.
